Schulte Roth & Zabel represented lead financier Deep Track Capital in an investment in TORL BioTherapeutics, a clinical-stage biotechnology company involved in the discovery and development of immunotherapies designed to improve and extend the lives of patients with cancer worldwide. 

The oversubscribed $158 million Series B-2 financing spearheaded by Deep Track Capital, an investment firm focused exclusively on the life sciences industry, will advance a clinical-stage Antibody-Drug Conjugate. 

The Schulte team was led by partner Michael Flynn and special counsel John Doherty.